Ms. Dori Schatell and Dr. John Agar use a novel and unique approach to successfully take on the herculean task of explaining treatment options for chronic kidney disease when an individual needs dialysis. In so doing, they have introduced a new frontier in dialysis education.
New research has uncovered a process that is defective in patients with autosomal dominant polycystic kidney disease, a common cause of kidney failure. The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), point to a new potential strategy for preventing and treating the disease.
A biomarker test developed initially to identify early acute kidney injury (AKI) after surgery has been shown to successfully detect AKI in emergency room patients with a variety of urgent health issues.
A new, international study from the Chronic Kidney Disease Prognosis Consortium found that use of blood levels of cystatin C to estimate kidney function – alone or in combination with creatinine – strengthens the association between kidney function and risks of death and end-stage renal disease.
A new study of the megabladder mouse model suggests that tracking changes in the expression of key genes involved in kidney disease could help physicians predict the severity of urinary tract obstruction in pediatric patients, which could help identify children at the greatest risk of chronic kidney disease and permanent organ damage.
Given that there is one more year to go, the majority of the healthcare organizations should be prepared and ready to accept ICD-10 codes. Payers face a major challenge in working with providers and various clearinghouses to make sure they can accept the codes and have done adequate testing well in advance to avoid any last minute glitches. Most payer organizations need to prepare for the testing phase of ICD-10, which is rather cumbersome and painful considering the sheer number of partners involved.